ST. PAUL, Minn., June 21, 2017 /PRNewswire/ -- EnteroMedics
Inc. (NASDAQ:ETRM), the developer of medical devices to treat
obesity, metabolic diseases and other gastrointestinal disorders,
today announced that Scott Shikora,
M.D, F.A.C.S., F.A.S.M.B.S., the Company's Consulting Medical
Director, Professor of Surgery at Harvard
Medical School and Director of the Center for Metabolic and
Bariatric Surgery at Brigham and Women's Hospital in Boston, will present information about the
Company's vBloc® Neurometabolic Therapy as part of a
presentation on neuromodulation for the treatment of obesity. The
presentation will take place at the upcoming XIX International
Congress of Surgery for Obesity and Metabolic Diseases,
June 28-July 1, Playa del
Carmen, Mexico.
"It is an honor to present important information about the role
of neuromodulation in the treatment of obesity at the XIX
International Congress of Surgery for Obesity and Metabolic
Diseases," said Dr. Shikora. "vBloc Therapy is the first and only
anatomy-preserving, minimally invasive neuromodulation device which
uses blocking therapy for the effective and safe treatment of
obesity."
The vBloc System works to control sensations of hunger
using a pacemaker-like device that is implanted under the skin
during a safe, minimally invasive procedure that does not alter or
remove any patient anatomy. The device can be adjusted to optimize
patients' therapy needs and works to give the patient a sensation
of fullness, empowering them to eat less, control their appetite,
and lose weight. Studies have shown that vBloc Therapy
produces meaningful weight loss in patients as well as meaningful
improvements in related comorbidity factors, such as hemoglobin A1c
(HbA1c), without the major lifestyle implications of traditional
weight-loss surgeries.
"Obesity remains a serious health condition that, if left
untreated, can have a significant negative impact on a person's
livelihood as well as lead to additional medical issues including
Type 2 diabetes and hypertension," said Dan
Gladney, EnteroMedics' President, Chief Executive
Officer and Chairman of the Board. "vBloc Therapy is a proven
cutting-edge treatment that not only helps patients lose weight,
but also provides a positive impact on these serious comorbid
conditions. Presentations at major conferences provide valuable
opportunities to educate bariatric surgeons on an international
scale, showcasing the body of evidence accumulated on this novel
approach for the treatment of obesity."
vBloc Therapy is approved for use in helping with weight loss in
people aged 18 years and older who are obese, with a BMI of 40 to
45 kg/m2, or a BMI of 35 to 39.9 kg/m2 with a
related health condition such as Type 2 diabetes, high blood
pressure, high cholesterol levels or obstructive sleep apnea who
have had a poor response to trying to lose weight under supervision
in the last 5 years.
About EnteroMedics Inc.
EnteroMedics is a medical device company focused on the
development and commercialization of technology to treat obesity
and metabolic diseases. vBloc® Neurometabolic Therapy, delivered by
an FDA-approved pacemaker-like device called the vBloc® System, is
designed to help patients feel full and eat less by intermittently
blocking hunger signals on the vagus nerve. EnteroMedics recently
acquired the Gastric Vest System™ through its acquisition
of BarioSurg, Inc. The Gastric Vest is an investigational,
minimally invasive, laparoscopically implanted medical device being
studied for weight loss in morbidly obese patients. The device
wraps around the stomach, emulating the effect of conventional
weight-loss surgery, and enables gastric volume reduction without
permanently changing patient anatomy.
Information about the vBloc® System and vBloc®
Neurometabolic Therapy
You should not have an implanted vBloc® System if you have
cirrhosis of the liver, high blood pressure in the veins of the
liver, enlarged veins in your esophagus or a significant hiatal
hernia of the stomach; if you need magnetic resonance imaging
(MRI); if you have a permanently implanted, electrical medical
device; or if you need a diathermy procedure using heat. The most
common related adverse events that were experienced during clinical
study of the vBloc System included pain, heartburn, nausea,
difficulty swallowing, belching, wound redness or irritation, and
constipation.
Talk with your doctor about the full risks and benefits of vBloc
Therapy and vBloc System. For additional prescribing information,
please visit www.enteromedics.com.
If you are interested in learning more about vBloc
Neurometabolic Therapy, please visit www.vbloc.com or
call 1-800-MY-VBLOC.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements generally can be identified
by the use of words such as "expect," "plan," "anticipate,"
"could," "may," "intend," "will," "continue," "future," other words
of similar meaning and the use of future dates. These
forward-looking statements are based on the current expectations of
our management and involve known and unknown risks and
uncertainties that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others: our limited history of operations; our losses
since inception and for the foreseeable future; our limited
commercial sales experience with our vBloc® System for the
treatment of obesity in the United
States or in any foreign market other than Australia and the European Community; the
competitive industry in which we operate; our ability to maintain
compliance with the Nasdaq continued listing requirements; our
ability to commercialize our vBloc® System; our dependence on third
parties to initiate and perform our clinical trials; the need to
obtain regulatory approval for any modifications to our vBloc®
System; physician adoption of our vBloc® System and vBloc®
Neurometabolic Therapy; our ability to obtain third party coding,
coverage or payment levels; ongoing regulatory compliance; our
dependence on third party manufacturers and suppliers; the
successful development of our sales and marketing capabilities; our
ability to raise additional capital when needed; international
commercialization and operation; our ability to attract and retain
management and other personnel and to manage our growth
effectively; potential product liability claims; the cost and
management time of operating a public company; potential healthcare
fraud and abuse claims; healthcare legislative reform; and our
ability to obtain and maintain intellectual property protection for
our technology and products. These and additional risks and
uncertainties are described more fully in the Company's filings
with the Securities and Exchange Commission, particularly those
factors identified as "risk factors" in the annual report on Form
10-K filed March 8, 2017 and
quarterly report on Form 10-Q filed May 15,
2017. We are providing this information as of the date of
this press release and do not undertake any obligation to update
any forward-looking statements contained in this document as a
result of new information, future events or otherwise.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/enteromedics-announces-vbloc-therapy-to-be-presented-by-keynote-speaker-at-major-international-obesity-conference-300477256.html
SOURCE EnteroMedics Inc.